MADISON, Wis.–(BUSINESS WIRE)–Aug 4, 2026–
Archeus Technologies, a medical-stage company advancing a portfolio of differentiated small-molecule radiopharmaceutical therapies (RPTs) to address a couple of of the most advanced-to-tackle cancers, this day announced the reconstitution of its Advisory Board, appointing 5 leaders with deep abilities across medical constructing, drug discovery, and biopharmaceutical leadership.
“The Advisory Board has been rebuilt to reflect the attach Archeus is this day — a company with two piquant Segment 1 programs and a pipeline of contemporary sources at the encourage of them,” mentioned Norman LaFrance, M.D., chair of Archeus’ Advisory Board. “These 5 advisors had been chosen because their abilities maps straight away to the selections Archeus is making now — advancing two medical programs in radiopharmaceutical therapy, deepening a differentiated pipeline, and translating modern science into proof of thought. Every of them is a recognized leader in their topic, and together they characterize a meaningful transition within the caliber of abilities Archeus has dropped at the desk.”
“This board reflects the company we are becoming,” mentioned Evan Sengbusch, Ph.D., president and chief govt officer of Archeus Technologies. “We are going in a more demanding segment of constructing, and we’re constructing the leadership around us to examine that ambition. The abilities we’ve assembled positions Archeus to roam up — across the sanatorium, the pipeline, and the partnerships that might clarify our subsequent chapter.”
The 5 novel people of the Archeus Advisory Board are:
Jeremie Calais, M.D., Ph.D., is professor and director of the Clinical Study Program at UCLA’s Ahmanson Translational Theranostics Division, and a college member at the Jonsson Entire Cancer Middle and the Institute of Urologic Oncology. A number one researcher in prostate most cancers imaging and theranostics, he serves as valuable investigator of randomized Segment 2 and Segment 3 trials in PSMA PET imaging and PSMA radionuclide therapy. The Ahmanson Translational Theranostics Division submitted, jointly with UCSF, the educational NDA for ⁶⁸Ga-PSMA-11 — the first FDA-approved PSMA PET imaging agent for prostate most cancers. Dr. Calais bought his M.D. from the University of Paris-Diderot and is board-certified in nuclear treatment in France.
Lawrence Fong, M.D., is scientific director of the Immunotherapy Built-in Study Middle at Fred Hutch Cancer Middle. A doctor-scientist aroused about most cancers immunotherapy, Dr. Fong has contributed to the attain of FDA-approved immunotherapies including sipuleucel-T and immune checkpoint inhibitors, and led medical trials combining immune checkpoint inhibitors with radiopharmaceuticals including radium-223 and PSMA-lutetium-177. He is a recipient of the National Cancer Institute Effectively-known Investigator Award and acquired his M.D. and carried out his fellowship in medical oncology at Stanford University.
Marco Gottardis, Ph.D., is the proprietor of Gottardis Biotech LLC, a biopharmaceutical consultancy, and beforehand served as vice chairman of oncology innovation at Janssen Prescribed tablets (Johnson & Johnson). He spent 9 years leading Janssen’s prostate most cancers analysis and constructing portfolio as vice chairman and prostate most cancers program leader, and 14 years prior in oncology discovery analysis at Bristol Myers Squibb. He has led groups guilty for advancing constructing candidates from IND by Segment 2 proof of thought, and contributed to more than one FDA-approved therapies. Dr. Gottardis holds a B.S. in Biology from Columbia University and a Ph.D. in Human Oncology from the University of Wisconsin–Madison.
Jonathan Younger, Ph.D., most no longer too lengthy ago served as chief scientific officer of WARF Therapeutics, the Wisconsin Alumni Study Basis’s drug discovery program. All the diagram in which by his eight-300 and sixty five days tenure, his crew reviewed larger than 60 University of Wisconsin–Madison analysis alternatives and evolved three constructing candidates to licensing, including WT-7695 (now SKL37321), a CA9 radiopharmaceutical licensed to SK Biopharmaceuticals in November 2025. Earlier, Dr. Younger held senior chemistry leadership roles at Regulus Therapeutics, Celgene, and Merck Study Laboratories. He bought his Ph.D. in Chemistry from Michigan Impart University.
Stuart Grossman, M.D., is professor of oncology at the Johns Hopkins Kimmel Cancer Middle. For the previous 22 years, he has served as valuable investigator and director of Central Operations for the National Cancer Institute-funded Segment 1/2 mind tumor consortia, including the Grownup Mind Tumor Consortium. Dr. Grossman has led many Segment 1, 2, and 3 translational and medical mind most cancers analysis tasks, with abilities in designing and directing mountainous, multicenter, multidisciplinary medical trial groups — abilities straight away appropriate as Archeus expands its early-segment medical footprint across more than one programs. He bought his M.D. from the University of Rochester College of Treatment and carried out his fellowship in medical oncology at the Johns Hopkins University College of Treatment.
About Archeus Technologies
Archeus Technologies is a medical-stage company advancing a portfolio of differentiated small-molecule radiopharmaceutical therapies (RPTs) to address a couple of of the most advanced-to-tackle cancers. Starting with its Segment 1 therapeutic candidate, ARC-706, the company has assembled a rising pipeline of contemporary RPT agents with the capacity to fabricate curative responses to sufferers with evolved disease. Archeus is led by an govt crew with deep abilities in radiopharmaceutical discovery, isotope chemistry, and medical translation. To boot, Archeus has a lengthy-standing strategic collaboration with the University of Wisconsin–Madison (UW), a world leader in radiopharmaceuticals and theranostics, which permits privileged salvage admission to to leading radiochemistry, imaging, dosimetry, and analytical capabilities to boost meaningful development in this extremely technical home. To learn more, discuss over with ArcheusTech.com.
Glance supply version on businesswire.com:https://www.businesswire.com/data/dwelling/20260804897455/en/
CONTACT: Media Contact
Emma Yang
Supreme Communications
(908) 391-7197
KEYWORD: WISCONSIN UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS GENERAL HEALTH RADIOLOGY PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Archeus Technologies
Copyright Alternate Wire 2026.
PUB: 08/04/2026 09:00 AM/DISC: 08/04/2026 09:01 AM
http://www.businesswire.com/data/dwelling/20260804897455/en
